Friday, November 22, 2024
11/22/2024
Tarzana Treatment Centers, Inc. (TTC) will increase access to opioid overdose emergency treatment in Los Angeles County (LAC) by providing technical assistance to prescribers, emergency department (ED) personnel, and pharmacists to improve their capacity to respond to LAC’s growing opioid epidemic. TTC’s Opioid Overdose Treatment Access Technical Assistance (OD-TA) Program will address identified service gaps to expand community access to naloxone for emergency opioid overdose treatment. The OD-TA Program will provide training and technical assistance to LAC prescribers and EDs in the establishment or revamping of opioid overdose education and naloxone distribution programs as well as public health detailing at local pharmacies that carry naloxone to share best practices for opioid overdose prevention. TTC will leverage four (4) decades of experience as a substance use disorder (SUD) treatment provider, including the last twenty (20) years with an opioid treatment program, as well as its current countywide Hub & Spoke medication-assisted treatment (MAT) program and participation in LAC’s opioid safety coalition Safe Med LA to engage key community sectors. The specific goals of the OD-TA Program are to: 1) Increase the capacity of local prescribers to establish a program to prescribe/co-prescribe naloxone; 2) Increase the capacity of local EDs to prescribe/co-prescribe naloxone and screen and refer opioid overdose patients to SUD treatment, including MAT; and 3) Increase the capacity of local pharmacies to respond to the increased demand for naloxone. Specific activities and measurable process objectives include the following: 1) Compile existing resources at the local, state and national levels, including SAMHSA’s Opioid Overdose Prevention Toolkit, to develop two (2) Opioid Overdose Prevention Best Practices Toolkits, one (1) targeting prescribers and one (1) targeting ED personnel; 2) Develop training modules based on the Toolkits and deliver training to a minimum of 450 prescribers and 270 ED providers during the lifetime of the project; 3) Develop a Naloxone Action Kit for Pharmacies and conduct a minimum of 225 pharmacy visits during the lifetime of the project; 4) Purchase a minimum of 500 nasal naloxone (NARCAN®) kits or cartons with two (2) 4mg doses each and distribute them free of charge to patients at highest risk for opioid overdose who are ineligible to be prescribed naloxone; 5) Provide ongoing technical assistance to participating EDs in the establishment of protocols for connecting overdose patients with SUD treatment, including MAT; and 6) Provide comprehensive treatment and individualized treatment, including MAT, to referred patients. Additional outcome measures include a reduction in the rate of ED visits and hospitalizations due to opioid overdose, an increase in Naloxone prescriptions among participating prescribers, an increase in referrals to OUD treatment from participating EDs, and an increased awareness among pharmacy staff of opioid overdose prevention best practices at follow-up.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
